Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

People Briefs: St. Jude Medical, JenaValve Technology, Staar Surgical, ElectroCore

This article was originally published in The Gray Sheet

Executive Summary

St. Jude Medical names Zimmer Biomet CEO David Dvorak to board of directors, JenaValve appoints CFO, electroCore taps chief medical officer, and Staar Surgical names VP, research & development.

You may also be interested in...



Zimmer, Biomet Sell Off Some U.S. Assets As They Finalize A $14 Bil. Merger

Zimmer Biomet is now the second-largest orthopedic device maker behind Johnson & Johnson now that the merger between the two firms is complete. The companies divested some U.S. knee, elbow and bone cement assets in conjunction with finalized the deal after having sold of some European assets earlier in the year.

US FDA’s June User Fee Calendar Starts Out Steady, But A Crescendo Of Decisions Will Start Mid-Month

Two gene therapies and two novel inhibitors of JAK kinases are among the upcoming goal dates from the Pink Sheet’s US FDA Performance Tracker.

Supplemental Filings: FDA Expands In-Person Meeting Eligibility Again; Marks Suggests Sponsors Invite Foreign Regulators To FDA Meetings

More formal meetings are available for in-person sessions with the US FDA. Also, CBER Director Peter Marks offers advice for conducting meetings, from how to do hybrid right to how to include patient groups and foreign regulators.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT034119

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel